Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University, India. She has trained in internal medicine at Massachusetts General Hospital (MGH) and completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute, Boston. Dr. Raje has a joint faculty appointment at MGH and Dana-Farber Cancer Institute. She is a professor of medicine at Harvard Medical School and is the director of the Multiple Myeloma Program, Medical Oncology, at MGH. As a hematologist/oncologist at MGH, Dr. Raje’s primary focus is in multiple myeloma and related research. Her research focuses on understanding the biology of multiple myeloma and development of novel therapeutics for the treatment of myeloma. In basic research she has been involved with understanding the role of B cell activating factor (BAFF) and cyclin-D dysregulation in myeloma. She is also involved with understanding the biology of bone disease in myeloma. On the translational front, she has researched on several interesting antibodies and small molecules including BAFF antibody and cyclin-D1 inhibitors which have been validated preclinically and are being translated to phase I/II clinical studies for relapsed refractory myeloma.
Dr Raje is a member of the International Myeloma Working Group and National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Committee for Multiple Myeloma. She is a member of the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, and American Association of Cancer Research, she is also an ad hoc reviewer for several journals including Blood, Clinical Cancer Research, Leukemia, and the American Journal of Hematology. Dr. Raje is the recipient of several awards and has published extensively in the field of multiple myeloma research.
EM-59168 - Date of preparation: April 2021